Evidence map›Paper›PMID 22241091›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2012

"What does it mean?": uncertainties in understanding results of chromosomal microarray testing.

Marian Reiff, Barbara A Bernhardt, Surabhi Mulchandani, Danielle Soucier, Diana Cornell, Reed E Pyeritz, Nancy B Spinner

Open access · greenAbstract read
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  10. Article
  11. Article
  12. Delayed diagnosis and racial bias in children with genetic conditions.American journal of medical genetics. Part A · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Marian ReiffCenter for the Integration of Genetic Healthcare Technologies, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Marian.Reiff@uphs.upenn.edu
Barbara A Bernhardt
Surabhi Mulchandani
Danielle Soucier
Diana Cornell
Reed E Pyeritz
Nancy B Spinner
Translational Therapeutics (United States) · USChildren's Hospital of Philadelphia · USCenter for Human Genetics · USUniversity of Pennsylvania · US

Funding

Penn Center for ELSI Research in Emerging Genetic Technologies in Health CareP50HG004487 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI PYERITZ, REED E · 2007 to 2012
$6.2M
NHGRI NIH HHS P50 HG004487
6 · The paper itself

Abstract

purposeThe increased sensitivity of chromosomal microarray (CMA) technology as compared with traditional cytogenetic analysis allows for improved detection of genomic alterations. However, there is potential for uncertainty in the interpretation of test results in some cases. This paper explores how families understand and make meaning of CMA test results, and identifies the needs of families undergoing CMA testing.

methodsWe conducted semistructured interviews with parents of 25 pediatric outpatients with CMA test results indicating either a pathogenic alteration or a variant of unknown significance (VUS). Interviews were analyzed qualitatively.

resultsThree domains of understanding were identified: comprehension of results, interpretations of scientific uncertainty, and personal meaning for the child and family. Incomplete comprehension of test results and scientific uncertainty were prominent themes for families receiving results in both the VUS and pathogenic categories. Receiving results from non-geneticists and by telephone, long waits to see a geneticist, and misleading Internet searches all contributed to misunderstandings.

conclusionDifferentiating domains of understanding allows for the identification of uncertainties that can be reduced or managed in order to improve understanding of CMA results. Using this framework, we suggest interventions to promote clarity and address the informational needs of families undergoing CMA testing.

Indexed as

Microarray AnalysisPatient Education as TopicUncertaintyChromosomes, HumanData CollectionGenetic CounselingGenetic TestingHumansInterviews as TopicOutpatientsParentsPediatrics

Identifiers

PMID22241091
PMCPMC3445036
OpenAlexW2111210947

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.